RVMD Today - Aug 10: Stays Steady Amid News

カートのアイテムが多すぎます

ご購入は五十タイトルがカートに入っている場合のみです。

カートに追加できませんでした。

しばらく経ってから再度お試しください。

ウィッシュリストに追加できませんでした。

しばらく経ってから再度お試しください。

ほしい物リストの削除に失敗しました。

しばらく経ってから再度お試しください。

ポッドキャストのフォローに失敗しました

ポッドキャストのフォロー解除に失敗しました

RVMD Today - Aug 10: Stays Steady Amid News

無料で聴く

ポッドキャストの詳細を見る

Hey there! It’s Joey here, your friendly investor buddy, and I’ve been in the game for a while. Today, we're chatting about Revolution Medicines, or RVMD for short. It was kind of a chill day, barely moved, just a tiny uptick of 0.16%.

So, what went down? Well, RVMD had a pretty steady day. It didn’t get smoked, but it didn’t exactly shoot for the stars either. Just a slow and steady vibe. The trading volume was right around the average, so nothing too wild happening there.

Now, why did it play out this way? Some interesting stuff came to light. TD Cowen kept the stock rating at a solid Buy, which is a thumbs-up for RVMD. That probably gave some investors a little boost of confidence. Also, BeOne snagged exclusive rights to four cancer medicines in certain Asian markets. That’s a big deal, right? More markets mean more potential sales. Plus, there’s been a growing demand for Daraxonrasib, one of their treatments. People are talking about it, and it sounds like that’s been helping RVMD bounce back a bit after some rough patches.

Oh, and get this: Assenagon Asset Management picked up over 200,000 shares of RVMD. Major institutional buying can be a good sign, showing that some big players are betting on the stock.

Now, looking ahead, Revolution Medicines is still in the game with Daraxonrasib and its pipeline. So, there’s definitely stuff cooking.

Alright, that’s a wrap for today! Just remember, this is all for fun and info, not financial advice. Catch you later!

まだレビューはありません